]>
IRCT20180307038989N1 IRCT 2018-04-15 Mashhad University of Medical Sciences Effect of cilostazol on Schizophrenia The effect of adding Cilostazol on cognitive deficits and symptoms of schizophrenic patients: a double-blind, randomized clinical trial 2018-04-05 anticipated 60 Complete https://irct.ir/trial/30045 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Randomization description: Patients who completed entry and exit conditions in the study based on random numbers table were randomly assigned to two groups of drugs and placebo, Blinding description: The study is double blind: the form of drug and placebo is the same, and the evaluator, the patient and the analyst are not aware of what treatment they are using, and drug intervention is identified by the pharmacist in sealed envelopes with a numeric code. 3 Schizophrenia. Intervention 1: Intervention group: Cilostazol tablets are orally administered at a dose of 25 mg twice daily for 2 weeks and then 50 mg twice daily for 6 weeks. Intervention 2: Control group: placebo tablets similar to Cilostazol are orally administered at a dose of 25 mg twice daily for 2 weeks and then 50 mg twice daily for 6 weeks. Yes - There is a plan to make this available What will be shared: The total individual participants' data and the results of the study after the deidentification of the individuals are shared. When: starting in April 2019 To whom: All researchers are able to access the study results Conditions: Unidentifiable information is not shared with another organization Where to obtain: Unidentifiable information is not available to applicants How to obtain: Study data is published in the course of the paper and no other personal data is available to applicants Comments:
public Mohammadreza Fayyazi Bordbar
Ebne-sina hospital research center, Horre ameli avenue, Mashhad
Mashhad Iran (Islamic Republic of) 9195983134 +98 51 3711 2701 fayyazimr@mums.ac.ir Mashhad University of Medical Sciences scientific Mohammadreza Fayyazi Bordbar
Ebne-sina hospital research center, Horre ameli avenue, Mashhad
Mashhad Iran (Islamic Republic of) 9195983134 +98 51 3711 2701 fayyazimr@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Diagnosis of schizophrenia based on DSM-5 criteria aged 18-64 years completed consent form by the patient or his family at least the eighth grade education 18 years 64 years Both Simultaneous psychiatric disorders liver disorders medical illness Use of opioid substances other than cigarettes A hypersensitivity reaction or any untoward side effects caused by the drug Use of other interfering drugs Serious cognitive impairment blood or Platelet problem Contradictory with taking medication F20 Schizophrenia Treatment - Drugs Placebo Intervention group: Cilostazol tablets are orally administered at a dose of 25 mg twice daily for 2 weeks and then 50 mg twice daily for 6 weeks. Control group: placebo tablets similar to Cilostazol are orally administered at a dose of 25 mg twice daily for 2 weeks and then 50 mg twice daily for 6 weeks. Score in PANSS questionnaire. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Schizophrenia symptoms assessment questionnaire PANSS. Memory score in digit span. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Digit span questionnaire. Cognition scoring based on Wisconsin card sorting test. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Wisconsin card sorting test. Mashhad University of Medical Sciences Approved 2017-10-08 ethics committee of Mashhad university of medical sciences ghoreishi department, daneshgah ave, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)